Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
35.42%
0%
35.42%
6 Months
7.44%
0%
7.44%
1 Year
20.37%
0%
20.37%
2 Years
35.42%
0%
35.42%
3 Years
-33.33%
0%
-33.33%
4 Years
-49.96%
0%
-49.96%
5 Years
-46.37%
0%
-46.37%
Kromek Group Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.11%
EBIT Growth (5y)
24.57%
EBIT to Interest (avg)
-5.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
0.29
Tax Ratio
3.73%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.77
EV to EBIT
8.29
EV to EBITDA
4.31
EV to Capital Employed
0.76
EV to Sales
1.48
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
9.22%
ROE (Latest)
7.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Apr'23
Apr'23
Apr'22
Change(%)
Net Sales
17.30
12.10
42.98%
Operating Profit (PBDIT) excl Other Income
-1.60
-2.60
38.46%
Interest
1.20
0.60
100.00%
Exceptional Items
0.10
1.50
-93.33%
Consolidate Net Profit
-6.10
-4.90
-24.49%
Operating Profit Margin (Excl OI)
-366.60%
-578.00%
21.14%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2023 is 42.98% vs 16.35% in Apr 2022
Consolidated Net Profit
YoY Growth in year ended Apr 2023 is -24.49% vs 9.26% in Apr 2022
About Kromek Group Plc 
Kromek Group Plc
Pharmaceuticals & Biotechnology
Kromek Group plc is a radiation detection technology company. The Company develops radiation detectors based on cadmium zinc telluride. The Company's segments are UK Operations and US Operations. The Company designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets. The Company's solutions provide information on material composition and structure to enable the identification of cancerous tissues and hazardous materials (including explosives), and the analysis of radioactive materials. Its nuclear products include CPG, GR1-Gamma Ray Spectrometer, GR1A, SIGMA, TN15, RayMon10, Quant Air and RENA-Mini Development Platform. It offers detectors and subcomponents for original equipment manufacturer (OEM) customers in the medical imaging market, including computed tomography (CT), single photon emission computed tomography (SPECT), positron emission tomography (PET) and bone mineral densitometry.
Company Coordinates 
Company Details
Netpark Incubator, Thomas Wright Way , STOCKTON-ON-TEES None : TS21 3FD
Registrar Details






